BioSpace News Archive

Atamyo Therapeutics announced the filing of a Clinical Trial Application in Europe for ATA-200, its gene therapy targeting γ-sarcoglycan related limb-girdle muscular dystrophy Type 2C/R5.

Perosphere Technologies has announced the receipt of two prestigious federal grants: a Direct Phase II Small Business Innovation Research grant from the National Heart, Lung, and Blood Institute, part of the National Institutes of Health, and a subaward through an Atlanta Center for Microsystems Engineered Point-of-Care Technologies Center Grant, funded by the National Institute of Biomedical Imaging and Bioengineering.

CorriXR Therapeutics, Inc., an oncology-focused biotherapeutics company developing breakthrough technology that overcomes drug resistance in solid tumors, announced that Deborah Moorad, MBA, has been named the company’s new chief executive officer.

Annexon, Inc. announced that Douglas Love, president and chief executive officer, will participate in a fireside chat during the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, 2023 at 8:10 a.m. ET in NYC.

BioLoomics , the company pioneering directed evolution of target degrading antibodies using human cells, today announced it has raised $8.7 million in seed financing to advance its proprietary platform technology and antibody degrader programs.

Anokion Announces Nature Biomedical Engineering Publication Further Validating its Immune Tolerance Approach to Treating Celiac Disease and Multiple Sclerosis.

bioAffinity Technologies, Inc. announces the acquisition of the laboratory assets of Village Oaks Pathology Services, P.A., d/b/a Precision Pathology Services, a clinical laboratory accredited by the College of American Pathologists (CAP) and certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988.

AuraVax Therapeutics, Inc. today announced that their partners at the University of Houston presented data at Keystone Symposia: Vaccinology During and After COVID-19 taking place from September 17-20, 2023.

Horizon Therapeutics plc announced it has been named No. 1 on the Fortune Best Workplaces in Biopharma 2023 list in the large company category.

Anixa Biosciences, Inc. today announced that it has established a Cancer Business Advisory Board (CBAB), whose purpose is to provide guidance on the Company’s clinical and business development initiatives.